RxDoctor Payments Data

Avinash Chenam, MD

Urology · San Bernardino, CANPI 1841502986

Payments from drug & device makers

$75,330in general payments, 2019–2025

Across 391 payments — averaging $192.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$64K
  • Procept Biorobotics Corporation$3K
  • Biotissue Holdings Inc.$1K
  • Boston Scientific$1K
  • AbbVie$832
  • Davol Inc.$539
  • plus $5K from 35 others

What the payments were for

  • Speaking & faculty fees$4,5006%
  • Travel & lodging$8,08511%
  • Food & beverage$11,24915%
  • Education$51,49668%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$75,330 in reported general payments places this provider in the 90th percentile of 1,324 urology providers in California.

See all urology providers in California

Medicare billing

Part B allowed, 2024
$221,607
Medicare patients
531
Services billed
1,358

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide47$632,735
MyrbetriqMirabegron190$141,054
OrgovyxRelugolix21$58,579
GemtesaVibegron54$49,867
XgevaDenosumab11$32,592
Tamsulosin Hcl586$9,099
Estradiol141$8,861
Methenamine Hippurate26$3,214
Finasteride239$2,966
Oxybutynin Chloride ErOxybutynin Chloride124$2,678
Testosterone Cypionate56$2,361
Cephalexin192$1,265
NitrofurantoinNitrofurantoin Macrocrystal48$1,081
Dutasteride17$967
Solifenacin Succinate23$798

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$515$773,788237 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$363$108,44675 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,324 urology providers in California.

Other urology in San Bernardino

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →